Pharmaceuticals - Global Group of Eight - G8 - Industry Guide

Report Overview

Table of Contents

790

Select License Type

£790.00	Electronic License Electronic License An electronic version (mostly PDF, but can be Excel or PPT), which is either available for immediate download or will be sent via email by the Publisher of the report. The licencing for an electronic version is for use by the purchaser ONLY.
£1,975.00	Corporate License Corporate License An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is/are intended for use by an organisation in its entirety. For example, if reports are put on an Intranet or if they are distributed or used by more than one office, division, or country operation, then a Corporate Licence is required.

£790.00	Add to Wishlist
Change Currency	GBP EURO USD
	Order By Fax

Market	Healthcare and Medical
Report Type	Market Research
Country	Global
Published	1 April 2009
Number of Pages	238
Report Delivery	Email
Delivery Lead Time	-
Publisher	Datamonitor
File Format	-

This Pharmaceuticals - Global Group of Eight (G8) Industry Guide is an essential resource for top-level data and analysis covering the Pharmaceuticals industry in each of the G8 (United States, Canada, Germany, France, United Kingdom, Italy, Russia and Japan) countries. The report includes easily comparable data on market value, volume, segmentation and market share, plus full five year market forecasts. It examines future problems, innovations and potential growth areas within the market.

Scope of the Report

* Contains an executive summary and data on value, volume and segmentation

* Provides textual analysis of the industry's prospects, competitive landscape and profiles of the leading companies

* Incorporates in-depth five forces competitive environment analysis and scorecards

* Compares data from the US, Canada, Germany, France, UK, Italy, Russia and Japan, alongside individual chapters on each country. .

* Includes a five-year forecast of the industry

Highlights

The G8 Pharmaceuticals market grew by 4.2% between 2004 and 2007 to reach a value of $478.9 billion

In 2013, the market is forecast to have a value of $576.8 billion, an increase of 3.3% from 2008.

The US is the world’s largest market and generates 57% of global revenues.

Why you should buy this report

* Spot future trends and developments

* Inform your business decisions

* Add weight to presentations and marketing materials

* Save time carrying out entry-level research

Market Definition

The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare. Market values have been calculated at ex-factory prices (the value at which manufacturers sell the drugs to distributors).

Speak to an Advisor

Call us on
+44 (0) 203 086 8600

Select License Type

£790.00	Electronic License Electronic License An electronic version (mostly PDF, but can be Excel or PPT), which is either available for immediate download or will be sent via email by the Publisher of the report. The licencing for an electronic version is for use by the purchaser ONLY.
£1,975.00	Corporate License Corporate License An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is/are intended for use by an organisation in its entirety. For example, if reports are put on an Intranet or if they are distributed or used by more than one office, division, or country operation, then a Corporate Licence is required.

£790.00	Add to Wishlist
Change Currency	GBP EURO USD

TABLE OF CONTENTS
CHAPTER 1 INTRODUCTION 19
1.1 What is this report about? 19
1.2 Who is the target reader? 19
1.3 How to use this report 19
1.4 Definitions 19
CHAPTER 2 GROUP OF EIGHT (G8) PHARMACEUTICALS INDUSTRY OUTLOOK 20
CHAPTER 3 PHARMACEUTICALS IN CANADA 25
3.1 Market Overview 25
3.2 Market Value 26
3.3 Market Segmentation I 27
3.4 Market Segmentation II 28
3.5 Market Share 29
3.6 Five Forces Analysis 30
3.7 Leading Companies 38
3.8 Market Forecasts 49
3.9 Macroeconomic Indicators 50
CHAPTER 4 PHARMACEUTICALS IN FRANCE 52
4.1 Market Overview 52
4.2 Market Value 53
4.3 Market Segmentation I 54
4.4 Market Segmentation II 55
4.5 Market Share 56
4.6 Five Forces Analysis 57
4.7 Leading Companies 65
4.8 Market Forecasts 74
4.9 Macroeconomic Indicators 75
CHAPTER 5 PHARMACEUTICALS IN GERMANY 77
5.1 Market Overview 77
5.2 Market Value 78
5.3 Market Segmentation I 79
5.4 Market Segmentation II 80
5.5 Market Share 81
5.6 Five Forces Analysis 82
5.7 Leading Companies 91
5.8 Market Forecasts 103
5.9 Macroeconomic Indicators 104
CHAPTER 6 PHARMACEUTICALS IN ITALY 106
6.1 Market Overview 106
6.2 Market Value 107
6.3 Market Segmentation I 108
6.4 Market Segmentation II 109
6.5 Market Share 110
6.6 Five Forces Analysis 111
6.7 Leading Companies 120
6.8 Market Forecasts 131
6.9 Macroeconomic Indicators 132
CHAPTER 7 PHARMACEUTICALS IN JAPAN 134
7.1 Market Overview 134
7.2 Market Value 135
7.3 Market Segmentation I 136
7.4 Market Segmentation II 137
7.5 Market Share 138
7.6 Five Forces Analysis 139
7.7 Leading Companies 147
7.8 Market Forecasts 156
7.9 Macroeconomic Indicators 157
CHAPTER 8 PHARMACEUTICALS IN RUSSIA 159
8.1 Market Overview 159
8.2 Market Value 160
8.3 Market Segmentation I 161
8.4 Market Segmentation II 162
8.5 Market Share 163
8.6 Five Forces Analysis 164
8.7 Leading Companies 172
8.8 Market Forecasts 179
8.9 Macroeconomic Indicators 180
CHAPTER 9 PHARMACEUTICALS IN THE UNITED KINGDOM 182
9.1 Market Overview 182
9.2 Market Value 183
9.3 Market Segmentation I 184
9.4 Market Segmentation II 185
9.5 Market Share 186
9.6 Five Forces Analysis 187
9.7 Leading Companies 195
9.8 Market Forecasts 207
9.9 Macroeconomic Indicators 208
CHAPTER 10 PHARMACEUTICALS IN THE UNITED STATES 210
10.1 Market Overview 210
10.2 Market Value 211
10.3 Market Segmentation I 212
10.4 Market Segmentation II 213
10.5 Market Share 214
10.6 Five Forces Analysis 215
10.7 Leading Companies 223
10.8 Market Forecasts 236
10.9 Macroeconomic Indicators 237
CHAPTER 11 APPENDIX 238
11.1 Data Research Methodology 238

LIST OF TABLES
Table 1: G8 Pharmaceuticals industry, revenue ($ bn), 2004–13 20
Table 2: G8 Pharmaceuticals industry, revenue by country ($ bn) 2004–2008(e) 22
Table 3: G8 Pharmaceuticals industry forecast, revenue by country ($ bn) 2008–2013 24
Table 4: Canada Pharmaceuticals Market Value: $ billion, 2004-2008 26
Table 5: Canada Pharmaceuticals Market Segmentation I: % Share, by Value, 2008(e) 27
Table 6: Canada Pharmaceuticals Market Segmentation II: % Share, by Value, 2008(e) 28
Table 7: Canada Pharmaceuticals Market Share: % Share, by Value, 2008(e) 29
Table 8: Key Facts: Pfizer Inc 38
Table 9: Key Financials: Pfizer Inc 40
Table 10: Key Facts: AstraZeneca PLC 41
Table 11: Key Financials: AstraZeneca PLC 43
Table 12: Key Facts: Apotex, Inc. 44
Table 13: Key Facts: Johnson & Johnson 46
Table 14: Key Financials: Johnson & Johnson 48
Table 15: Canada Pharmaceuticals Market Value Forecast: $ billion, 2008-2013 49
Table 16: Canada Size of Population (million) , 2004-2008 50
Table 17: Canada GDP (Constant 2000 Prices, $ billion), 2004-2008 50
Table 18: Canada Inflation, 2004-2008 51
Table 19: Canada Exchange Rate, 2004-2008 51
Table 20: France Pharmaceuticals Market Value: $ billion, 2004-2008 53
Table 21: France Pharmaceuticals Market Segmentation I: % Share, by Value, 2008(e) 54
Table 22: France Pharmaceuticals Market Segmentation II: % Share, by Value, 2008(e) 55
Table 23: France Pharmaceuticals Market Share: % Share, by Value, 2008(e) 56
Table 24: Key Facts: Sanofi-Aventis SA 65
Table 25: Key Financials: Sanofi-Aventis SA 66
Table 26: Key Facts: GlaxoSmithKline Plc 67
Table 27: Key Financials: GlaxoSmithKline Plc 70
Table 28: Key Facts: Pfizer Inc 71
Table 29: Key Financials: Pfizer Inc 73
Table 30: France Pharmaceuticals Market Value Forecast: $ billion, 2008-2013 74
Table 31: France Size of Population (million) , 2004-2008 75
Table 32: France GDP (Constant 2000 Prices, $ billion), 2004-2008 75
Table 33: France Inflation, 2004-2008 76
Table 34: France Exchange Rate, 2004-2008 76
Table 35: Germany Pharmaceuticals Market Value: $ billion, 2004-2008 78
Table 36: Germany Pharmaceuticals Market Segmentation I: % Share, by Value, 2008(e) 79
Table 37: Germany Pharmaceuticals Market Segmentation II: % Share, by Value, 2008(e) 80
Table 38: Germany Pharmaceuticals Market Share: % Share, by Value, 2008(e) 81
Table 39: Key Facts: Pfizer Inc 91
Table 40: Key Financials: Pfizer Inc 93
Table 41: Key Facts: Sanofi-Aventis SA 94
Table 42: Key Financials: Sanofi-Aventis SA 95
Table 43: Key Facts: AstraZeneca PLC 96
Table 44: Key Financials: AstraZeneca PLC 99
Table 45: Key Facts: Roche Holding Ltd. 100
Table 46: Key Financials: Roche Holding Ltd. 102
Table 47: Germany Pharmaceuticals Market Value Forecast: $ billion, 2008-2013 103
Table 48: Germany Size of Population (million) , 2004-2008 104
Table 49: Germany GDP (Constant 2000 Prices, $ billion), 2004-2008 104
Table 50: Germany Inflation, 2004-2008 105
Table 51: Germany Exchange Rate, 2004-2008 105
Table 52: Italy Pharmaceuticals Market Value: $ billion, 2004-2008 107
Table 53: Italy Pharmaceuticals Market Segmentation I: % Share, by Value, 2008(e) 108
Table 54: Italy Pharmaceuticals Market Segmentation II: % Share, by Value, 2008(e) 109
Table 55: Italy Pharmaceuticals Market Share: % Share, by Value, 2008(e) 110
Table 56: Key Facts: Sanofi-Aventis SA 120
Table 57: Key Financials: Sanofi-Aventis SA 121
Table 58: Key Facts: Menarini Group 122
Table 59: Key Facts: Pfizer Inc 124
Table 60: Key Financials: Pfizer Inc 126
Table 61: Key Facts: GlaxoSmithKline Plc 127
Table 62: Key Financials: GlaxoSmithKline Plc 130
Table 63: Italy Pharmaceuticals Market Value Forecast: $ billion, 2008-2013 131
Table 64: Italy Size of Population (million) , 2004-2008 132
Table 65: Italy GDP (Constant 2000 Prices, $ billion), 2004-2008 132
Table 66: Italy Inflation, 2004-2008 133
Table 67: Italy Exchange Rate, 2004-2008 133
Table 68: Japan Pharmaceuticals Market Value: $ billion, 2004-2008 135
Table 69: Japan Pharmaceuticals Market Segmentation I: % Share, by Value, 2008(e) 136
Table 70: Japan Pharmaceuticals Market Segmentation II: % Share, by Value, 2008(e) 137
Table 71: Japan Pharmaceuticals Market Share: % Share, by Value, 2008(e) 138
Table 72: Key Facts: Takeda Pharmaceutical Company Limited 147
Table 73: Key Financials: Takeda Pharmaceutical Company Limited 148
Table 74: Key Facts: Astellas Pharma 149
Table 75: Key Financials: Astellas Pharma 150
Table 76: Key Facts: Daiichi Sankyo Co., Ltd. 151
Table 77: Key Facts: Pfizer Inc 153
Table 78: Key Financials: Pfizer Inc 155
Table 79: Japan Pharmaceuticals Market Value Forecast: $ billion, 2008-2013 156
Table 80: Japan Size of Population (million) , 2004-2008 157
Table 81: Japan GDP (Constant 2000 Prices, $ billion), 2004-2008 157
Table 82: Japan Inflation, 2004-2008 158
Table 83: Japan Exchange Rate, 2004-2008 158
Table 84: Russia Pharmaceuticals Market Value: $ billion, 2004-2008 160
Table 85: Russia Pharmaceuticals Market Segmentation I: % Share, by Value, 2008(e) 161
Table 86: Russia Pharmaceuticals Market Segmentation II: % Share, by Value, 2008(e) 162
Table 87: Russia Pharmaceuticals Market Share: % Share, by Value, 2008(e) 163
Table 88: Key Facts: Novartis AG 172
Table 89: Key Financials: Novartis AG 174
Table 90: Key Facts: Sanofi-Aventis SA 175
Table 91: Key Financials: Sanofi-Aventis SA 176
Table 92: Key Facts: Menarini Group 177
Table 93: Russia Pharmaceuticals Market Value Forecast: $ billion, 2008-2013 179
Table 94: Russia Size of Population (million) , 2004-2008 180
Table 95: Russia GDP (Constant 2000 Prices, $ billion), 2004-2008 180
Table 96: Russia Inflation, 2004-2008 181
Table 97: Russia Exchange Rate, 2004-2008 181
Table 98: United Kingdom Pharmaceuticals Market Value: $ billion, 2004-2008 183
Table 99: United Kingdom Pharmaceuticals Market Segmentation I: % Share, by Value, 2008(e) 184
Table 100: United Kingdom Pharmaceuticals Market Segmentation II: % Share, by Value, 2008(e) 185
Table 101: United Kingdom Pharmaceuticals Market Share: % Share, by Value, 2008(e) 186
Table 102: Key Facts: Pfizer Inc 195
Table 103: Key Financials: Pfizer Inc 197
Table 104: Key Facts: GlaxoSmithKline Plc 198
Table 105: Key Financials: GlaxoSmithKline Plc 201
Table 106: Key Facts: Sanofi-Aventis SA 202
Table 107: Key Financials: Sanofi-Aventis SA 203
Table 108: Key Facts: AstraZeneca PLC 204
Table 109: Key Financials: AstraZeneca PLC 206
Table 110: United Kingdom Pharmaceuticals Market Value Forecast: $ billion, 2008-2013 207
Table 111: United Kingdom Size of Population (million) , 2004-2008 208
Table 112: United Kingdom GDP (Constant 2000 Prices, $ billion), 2004-2008 208
Table 113: United Kingdom Inflation, 2004-2008 209
Table 114: United Kingdom Exchange Rate, 2004-2008 209
Table 115: United States Pharmaceuticals Market Value: $ billion, 2004-2008 211
Table 116: United States Pharmaceuticals Market Segmentation I: % Share, by Value, 2008(e) 212
Table 117: United States Pharmaceuticals Market Segmentation II: % Share, by Value, 2008(e) 213
Table 118: United States Pharmaceuticals Market Share: % Share, by Value, 2008(e) 214
Table 119: Key Facts: Pfizer Inc 223
Table 120: Key Financials: Pfizer Inc 225
Table 121: Key Facts: GlaxoSmithKline Plc 226
Table 122: Key Financials: GlaxoSmithKline Plc 229
Table 123: Key Facts: Merck & Co., Inc. 230
Table 124: Key Financials: Merck & Co., Inc. 232
Table 125: Key Facts: Johnson & Johnson 233
Table 126: Key Financials: Johnson & Johnson 235
Table 127: United States Pharmaceuticals Market Value Forecast: $ billion, 2008-2013 236
Table 128: United States Size of Population (million) , 2004-2008 237
Table 129: United States GDP (Constant 2000 Prices, $ billion), 2004-2008 237
Table 130: United States Inflation, 2004-2008 237

LIST OF FIGURES
Figure 1: G8 Pharmaceuticals industry, revenue ($ bn) 2004–2013 20
Figure 2: G8 Pharmaceuticals industry, revenue by country (%) 2004–2013 21
Figure 3: G8 Pharmaceuticals industry, revenue by country ($ bn) 2004–2008(e) 22
Figure 4: G8 Pharmaceuticals industry forecast, revenue by country ($ bn) 2008–2013 23
Figure 5: Canada Pharmaceuticals Market Value: $ billion, 2004-2008 26
Figure 6: Canada Pharmaceuticals Market Segmentation I: % Share, by Value, 2008(e) 27
Figure 7: Canada Pharmaceuticals Market Segmentation II: % Share, by Value, 2008(e) 28
Figure 8: Canada Pharmaceuticals Market Share: % Share, by Value, 2008(e) 29
Figure 9: Forces Driving Competition in the Pharmaceuticals Market in Canada 30
Figure 10: Drivers of Buyer Power in the Pharmaceuticals Market in Canada 31
Figure 11: Drivers of Supplier Power in the Pharmaceuticals Market in Canada 32
Figure 12: Factors Influencing the Likelihood of New Entrants in the Pharmaceuticals Market in Canada 34
Figure 13: Factors Influencing the Threat of Substitutes in the Pharmaceuticals Market in Canada 36
Figure 14: Drivers of Degree of Rivalry in the Pharmaceuticals Market in Canada 37
Figure 15: Revenues & Profitability: Pfizer Inc 40
Figure 16: Revenues & Profitability: AstraZeneca PLC 43
Figure 17: Revenues & Profitability: Johnson & Johnson 48
Figure 18: Canada Pharmaceuticals Market Value Forecast: $ billion, 2008-2013 49
Figure 19: France Pharmaceuticals Market Value: $ billion, 2004-2008 53
Figure 20: France Pharmaceuticals Market Segmentation I: % Share, by Value, 2008(e) 54
Figure 21: France Pharmaceuticals Market Segmentation II: % Share, by Value, 2008(e) 55
Figure 22: France Pharmaceuticals Market Share: % Share, by Value, 2008(e) 56
Figure 23: Forces Driving Competition in the Pharmaceuticals Market in France 57
Figure 24: Drivers of Buyer Power in the Pharmaceuticals Market in France 58
Figure 25: Drivers of Supplier Power in the Pharmaceuticals Market in France 60
Figure 26: Factors Influencing the Likelihood of New Entrants in the Pharmaceuticals Market in France 62
Figure 27: Factors Influencing the Threat of Substitutes in the Pharmaceuticals Market in France 63
Figure 28: Drivers of Degree of Rivalry in the Pharmaceuticals Market in France 64
Figure 29: Revenues & Profitability: Sanofi-Aventis SA 66
Figure 30: Revenues & Profitability: GlaxoSmithKline Plc 70
Figure 31: Revenues & Profitability: Pfizer Inc 73
Figure 32: France Pharmaceuticals Market Value Forecast: $ billion, 2008-2013 74
Figure 33: Germany Pharmaceuticals Market Value: $ billion, 2004-2008 78
Figure 34: Germany Pharmaceuticals Market Segmentation I: % Share, by Value, 2008(e) 79
Figure 35: Germany Pharmaceuticals Market Segmentation II: % Share, by Value, 2008(e) 80
Figure 36: Germany Pharmaceuticals Market Share: % Share, by Value, 2008(e) 81
Figure 37: Forces Driving Competition in the Pharmaceuticals market in Germany 82
Figure 38: Drivers of Buyer Power in the Pharmaceuticals market in Germany 84
Figure 39: Drivers of Supplier Power in the Pharmaceuticals market in Germany 85
Figure 40: Factors Influencing the Likelihood of New Entrants in the Pharmaceuticals market in Germany 87
Figure 41: Factors Influencing the Threat of Substitutes in the Pharmaceuticals market in Germany 89
Figure 42: Drivers of Degree of Rivalry in the Pharmaceuticals market in Germany 90
Figure 43: Revenues & Profitability: Pfizer Inc 93
Figure 44: Revenues & Profitability: Sanofi-Aventis SA 95
Figure 45: Revenues & Profitability: AstraZeneca PLC 99
Figure 46: Revenues & Profitability: Roche Holding Ltd. 102
Figure 47: Germany Pharmaceuticals Market Value Forecast: $ billion, 2008-2013 103
Figure 48: Italy Pharmaceuticals Market Value: $ billion, 2004-2008 107
Figure 49: Italy Pharmaceuticals Market Segmentation I: % Share, by Value, 2008(e) 108
Figure 50: Italy Pharmaceuticals Market Segmentation II: % Share, by Value, 2008(e) 109
Figure 51: Italy Pharmaceuticals Market Share: % Share, by Value, 2008(e) 110
Figure 52: Forces Driving Competition in the Pharmaceuticals Market in Italy 111
Figure 53: Drivers of Buyer Power in the Pharmaceuticals Market in Italy 112
Figure 54: Drivers of Supplier Power in the Pharmaceuticals Market in Italy 114
Figure 55: Factors Influencing the Likelihood of New Entrants in the Pharmaceuticals Market in Italy 116
Figure 56: Factors Influencing the Threat of Substitutes in the Pharmaceuticals Market in Italy 118
Figure 57: Drivers of Degree of Rivalry in the Pharmaceuticals Market in Italy 119
Figure 58: Revenues & Profitability: Sanofi-Aventis SA 121
Figure 59: Revenues & Profitability: Pfizer Inc 126
Figure 60: Revenues & Profitability: GlaxoSmithKline Plc 130
Figure 61: Italy Pharmaceuticals Market Value Forecast: $ billion, 2008-2013 131
Figure 62: Japan Pharmaceuticals Market Value: $ billion, 2004-2008 135
Figure 63: Japan Pharmaceuticals Market Segmentation I: % Share, by Value, 2008(e) 136
Figure 64: Japan Pharmaceuticals Market Segmentation II: % Share, by Value, 2008(e) 137
Figure 65: Japan Pharmaceuticals Market Share: % Share, by Value, 2008(e) 138
Figure 66: Forces Driving Competition in the Pharmaceuticals Market in Japan 139
Figure 67: Drivers of Buyer Power in the Pharmaceuticals Market in Japan 140
Figure 68: Drivers of Supplier Power in the Pharmaceuticals Market in Japan 142
Figure 69: Factors Influencing the Likelihood of New Entrants in the Pharmaceuticals Market in Japan 144
Figure 70: Factors Influencing the Threat of Substitutes in the Pharmaceuticals Market in Japan 145
Figure 71: Drivers of Degree of Rivalry in the Pharmaceuticals Market in Japan 146
Figure 72: Revenues & Profitability: Takeda Pharmaceutical Company Limited 148
Figure 73: Revenues & Profitability: Astellas Pharma 150
Figure 74: Revenues & Profitability: Pfizer Inc 155
Figure 75: Japan Pharmaceuticals Market Value Forecast: $ billion, 2008-2013 156
Figure 76: Russia Pharmaceuticals Market Value: $ billion, 2004-2008 160
Figure 77: Russia Pharmaceuticals Market Segmentation I: % Share, by Value, 2008(e) 161
Figure 78: Russia Pharmaceuticals Market Segmentation II: % Share, by Value, 2008(e) 162
Figure 79: Russia Pharmaceuticals Market Share: % Share, by Value, 2008(e) 163
Figure 80: Forces Driving Competition in the Pharmaceuticals Market in Russia 164
Figure 81: Drivers of Buyer Power in the Pharmaceuticals Market in Russia 165
Figure 82: Drivers of Supplier Power in the Pharmaceuticals Market in Russia 166
Figure 83: Factors Influencing the Likelihood of New Entrants in the Pharmaceuticals Market in Russia 168
Figure 84: Factors Influencing the Threat of Substitutes in the Pharmaceuticals Market in Russia 170
Figure 85: Drivers of Degree of Rivalry in the Pharmaceuticals Market in Russia 171
Figure 86: Revenues & Profitability: Novartis AG 174
Figure 87: Revenues & Profitability: Sanofi-Aventis SA 176
Figure 88: Russia Pharmaceuticals Market Value Forecast: $ billion, 2008-2013 179
Figure 89: United Kingdom Pharmaceuticals Market Value: $ billion, 2004-2008 183
Figure 90: United Kingdom Pharmaceuticals Market Segmentation I: % Share, by Value, 2008(e) 184
Figure 91: United Kingdom Pharmaceuticals Market Segmentation II: % Share, by Value, 2008(e) 185
Figure 92: United Kingdom Pharmaceuticals Market Share: % Share, by Value, 2008(e) 186
Figure 93: Forces Driving Competition in the Pharmaceuticals Market in the UK 187
Figure 94: Drivers of Buyer Power in the Pharmaceuticals Market in the UK 189
Figure 95: Drivers of Supplier Power in the Pharmaceuticals Market in the UK 190
Figure 96: Factors Influencing the Likelihood of New Entrants in the Pharmaceuticals Market in the UK 192
Figure 97: Factors Influencing the Threat of Substitutes in the Pharmaceuticals Market in the UK 193
Figure 98: Drivers of Degree of Rivalry in the Pharmaceuticals Market in the UK 194
Figure 99: Revenues & Profitability: Pfizer Inc 197
Figure 100: Revenues & Profitability: GlaxoSmithKline Plc 201
Figure 101: Revenues & Profitability: Sanofi-Aventis SA 203
Figure 102: Revenues & Profitability: AstraZeneca PLC 206
Figure 103: United Kingdom Pharmaceuticals Market Value Forecast: $ billion, 2008-2013 207
Figure 104: United States Pharmaceuticals Market Value: $ billion, 2004-2008 211
Figure 105: United States Pharmaceuticals Market Segmentation I: % Share, by Value, 2008(e) 212
Figure 106: United States Pharmaceuticals Market Segmentation II: % Share, by Value, 2008(e) 213
Figure 107: United States Pharmaceuticals Market Share: % Share, by Value, 2008(e) 214
Figure 108: Forces Driving Competition in the Pharmaceutical Market in the US 215
Figure 109: Drivers of Buyer Power in the Pharmaceutical Market in the US 217
Figure 110: Drivers of Supplier Power in the Pharmaceutical Market in the US 218
Figure 111: Factors Influencing the Likelihood of New Entrants in the Pharmaceutical Market in the US 220
Figure 112: Factors Influencing the Threat of Substitutes in the Pharmaceutical Market in the US 221
Figure 113: Drivers of Degree of Rivalry in the Pharmaceutical Market in the US 222
Figure 114: Revenues & Profitability: Pfizer Inc 225
Figure 115: Revenues & Profitability: GlaxoSmithKline Plc 229
Figure 116: Revenues & Profitability: Merck & Co., Inc. 232
Figure 117: Revenues & Profitability: Johnson & Johnson 235
Figure 118: United States Pharmaceuticals Market Value Forecast: $ billion, 2008-2013 236

Visitor Comments

All Comments

Change Currency

GBP

EURO

USD

Last Viewed

Pharmaceuticals - Global Group of Eight - G8 - Industry Guide

Pharma Goes Cloud Gazing (Analyst Opinion)

Pet Supplies and Pet Care Products: The U.S. Market and a Global Perspective

Pet Supplies and Pet Care Products: Global Market Overview 2010

Pet Food and Pet Care Products in Saudi Arabia

Healthcare and Medical Company Profiles

Healthcare and Medical Company Profiles contain up to date financial, strategic, operational, SWOT analysis and product information on the activities of thousands of healthcare and medical companies.

Become an Affiliate

Do you manage an industry specific website or blog? Are you looking to monetise your web traffic further? Are you a B2B website?

Why not offer your visitors industry specific strategic market reports and company profiles? Our Affiliate Program enables you to provide quality content on your website and to earn money from passing on visitors to our website. If a sale is made from your visitor, you earn commission (a fixed percentage of the price of a product).

Custom Research

Cannot find what you need? We can tailor a report for you. Complete the Custom Research Form and we will provide a quote.

Healthcare and Medical	Type	Keywords Phrase All Words Any Word
Microsoft Windows users can hold the CTRL Key to select more than one sector or country at a time. Apple users can hold the CMD Key to do the same.	Country	Industry Sector
Publisher	Order By Relevance Date	Published In

Pharmaceuticals - Global Group of Eight - G8 - Industry Guide

Select License Type

Speak to an Advisor

Select License Type

Table of Contents

Visitor Comments

Change Currency

Last Viewed

Healthcare and Medical Company Profiles

Become an Affiliate

Custom Research

News

Market Insights

Companies And Markets

Customer Support

Corporate Accounts

Contact Details

Contrast settings

Text size settings

All
Afghanistan
Africa
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antigua and Barbuda
Argentina
Armenia
Aruba
Asia
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia-Herzegovina
Botswana
Bouvet Island
Brazil
British Virgin Islands
Brunei
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Caribbean
Cayman Islands
Central African Republic
Central America
Central Europe
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Conch Republic
Cook Islands
Costa Rica
Croatia
Cuba
Cyprus
Czech Republic
Democratic Republic of Congo
Denmark
Djibouti
Dominica
Dominican Republic
Eastern Europe
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Europe
Falkland Islands
Faroe Islands
Fiji
Finland
France
French Guiana
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Global
Greece
Greenland
Grenada
Guadeloupe (French)
Guam (USA)
Guatemala
Guernsey
Guinea
Guinea Bissau
Guyana
Haiti
Heard Island and McDonald Islans
Holy See
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran
Iraq
Ireland
Israel
Italy
Ivory Coast
Ivory Coast (Cote D`Ivoire)
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Kurdistan
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macau
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique (French)
Mauritania
Mauritius
Mayotte
Mexico
Micronesia
Middle East
Moldova
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
Netherlands Antilles
New Caledonia (French)
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
North America
North Korea
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territory
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn Island
Poland
Polynesia (French)
Portugal
Puerto Rico
Qatar
Reunion
Romania
Russia
Rwanda
Saint Barthelemy
Saint Helena
Saint Kitts and Nevis
Saint Lucia
Saint Martin
Saint Pierre and Miquelon
Saint Vincent and Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Scandinavia
Schengen countries
Senegal
Serbia and Montenegro
Seychelles
Sierra Leone
Singapore
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South America
South Georgia and the South Sandwich Islands
South Korea
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen Islands
Swaziland
Sweden
Switzerland
Syria
Taiwan
Tajikistan
Tanzania
Thailand
Timor-Leste (East Timor)
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
United States Minor Outlying Islands
Uruguay
Uzbekistan
Vanuatu
Venezuela
Vietnam
Virgin Islands
Wallis and Futuna Islands
Western Sahara
Yemen
Zambia
Zimbabwe

All
Aerospace
Agriculture, Farming & Raw Materials
Automotive and Parts
Business Services
Chemicals
Construction
Consumer Goods
Defence
Energy and Utilities
Environmental
Finance and Banking
Food and Drink
Healthcare and Medical
Industrial
Information Technology
Leisure
Logistics
Media
Paper and Packaging
Publishing and Printing
Real Estate
Retail
Security
Telecommunications
Textiles and Clothing
Transportation
Travel